PML/RARa融合基因监测急性早幼粒细胞白血病微小残留病的临床意义  

Evaluation of the Detection of PML-RARa Fusion Gene in Acute Promyelocytic Leukemia to Monitor Minimal Residual Disease

作　　者：黎承萍[1] 李淑娈[1] 李维佳[1] 

机构地区：[1]昆明医学院第一附属医院血液科,昆明650000

出　　处：《中国医药导刊》2008年第8期1247-1248,1250,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:观察PML/RARa融合基因在监测急性早幼粒细胞白血病(APL)微小残留病(MRD)中的临床意义。方法:诱导缓解及巩固维持治疗期间,采用筑巢式逆转录-聚合酶链反应(RT-PCR)技术检测患者骨髓细胞中PML-RARa融合基因的动态变化,PML-RARa融合基因。结果:长期随访的18例完全缓解(CR)患者,2例出现分子学复发。其中1例发生于CR1后后4个月,诱导缓解治疗后获得CR2, CR2后2个月再次出现分子学与血液学的复发,诱导治疗1个疗程获得CR3;1例发生于CR1后74个月,诱导缓解治疗后获得CR2,随访结束时生存期已达106个月。结论:在CR期定期监测PML-RARa融合基因,可早期发现分子学复发,及时干预治疗可避免血液学复发。Objective：To investigate the kinetics of PML-RARa fusion gene in acute promyelocytic leukemia（APL）to monitor minimal residual disease （MRD）.Methods：In induction therapy,consolidation and maintenance therapy courses , PML-RARa fusion gene was performed by RT-PCR.Results：The long-term follow-up of 18 cases who anhieved complete remission （CR）,two cases experienced molecular relapse.One case relapsed at 4 months after CR1 and achieved CR2 after induction therapy.Howere,molecular and hematology relapsed again at 2 months after CR2 and reachieved CR3.The other case relapsed at 74 months after CR1 and achieved CR2 after induction treatment,Who had survived for 106 montha untile the end of follow-up.Conclusion：RT-PCR assay for detection of PML-RARa shoud be performed regularly during CR period so to find molecular relapse early.hematological relapse could potentially be averted through tretment modification according to molecular monitoring results of PML-RARa.

关 键 词：急性早幼粒细胞白血病 PML-RARa融合基因 微小残留病 

分 类 号：R733.7[医药卫生—肿瘤]